98%
921
2 minutes
20
: The diagnostic accuracy of abdominal ultrasound (US) is operator-dependent and, therefore, influenced by inadequate training and lack of continuous medical education. To fill this gap, the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) has developed guidelines to identify minimum training requirements for US. The aim of our survey was to assess the self-reported overall US education level among young Italian gastroenterologists. : The Italian Association of Young Gastroenterologists and Endoscopists (Associazione Giovani Gastroenterologi ed Endoscopisti Italiani, AGGEI) developed a web-based survey with a multiple-choice test with images, based on the EFSUMB recommendations. The survey was distributed via e-mail to AGGEI members. : The questionnaire was filled out by 110 participants from all over Italy. Most of the respondents worked in academic hospitals and were gastroenterology residents or PhD students. More than half (58.9%) learned US during their gastroenterology training and 8.2% attended specific courses. During their training participants performed a median number of 320 abdominal USs and 240 bowel USs. Participants receiving a longer training period ranked significantly better in the knowledge questionnaire. : Young Italian gastroenterologists show heterogeneous training in residencies across the country. In the future learning and hands-on training courses endorsed by academies are needed to fill this knowledge and skill gap.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12027906 | PMC |
http://dx.doi.org/10.3390/jcm14082693 | DOI Listing |
Pharmaceuticals (Basel)
August 2025
State Key Laboratory of Quality Research in Chinese Medicine, School of Pharmacy, Macau University of Science and Technology, Macau SAR 999078, China.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by providing durable responses and a favorable safety profile, ushering in a new era of tumor immunotherapy. However, immune-related adverse events (irAEs) remain a significant clinical challenge. Among these, gastrointestinal irAEs, especially immune-related colitis (ir-colitis), can lead to serious complications if not promptly recognized and managed.
View Article and Find Full Text PDFJ Pediatr Gastroenterol Nutr
July 2025
C.S. Mott Children's Hospital, Michigan Medicine, Ann Arbor, Michigan, USA.
Inflammatory bowel diseases (IBD) require effective therapies to prevent morbidity and maintain quality of life. The introduction of biologic agents, beginning with monoclonal antibodies targeting tumor necrosis factor (TNF) alpha, has launched a new era of advancements that have markedly improved short- and long-term outcomes of Crohn's disease and ulcerative colitis. Along with these improvements, there have been challenges to address in optimizing use of biologic therapies in children with IBD.
View Article and Find Full Text PDFJ Hum Nutr Diet
August 2025
Department of Gastroenterology and Hepatology, Monash Health, Melbourne, Victoria, Australia.
Introduction: The role of diet in inflammatory bowel disease (IBD) remains controversial, with limited clinical guidelines available. There is increasing evidence of the potential role of diet as therapy in IBD. We conducted a survey nearly a decade ago assessing the perspectives of patients and clinicians on diet and IBD and found that whilst patients believed diet was important for IBD, clinicians had heterogeneous views.
View Article and Find Full Text PDFDrug Des Devel Ther
July 2025
Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
Background: The therapeutic potential of nifuroxazide in colitis has been explored in several experimental studies of ulcerative colitis (UC).
Aim: To evaluate the efficacy of nifuroxazide in patients with UC.
Methods: Fifty patients with mild to moderate UC were randomly assigned into two groups (n = 25 each).
Clin Transl Gastroenterol
June 2025
Exact Sciences Corporation, Madison, Wisconsin, USA.
Introduction: Recommendations for colorectal cancer (CRC) screening have been updated to include individuals aged 45-49 years, addressing recent increases in CRC rates among young adults. The multitarget stool DNA (mt-sDNA) test is approved for average-risk individuals aged 45-49 years and is a noninvasive, at-home, stool-based option. This real-world study quantified mt-sDNA screening adherence rates for individuals aged 45-49 years.
View Article and Find Full Text PDF